Review Article

Oxidative Stress and \( \beta \)-Thalassemic Erythroid Cells behind the Molecular Defect

Lucia De Franceschi, Mariarita Bertoldi, Alessandro Matte, Sara Santos Franco, Antonella Pantaleo, Emanuela Ferru, and Franco Turrini

1 Department of Medicine, Section of Internal Medicine, University of Verona, Policlinico GB Rossi, 37134 Verona, Italy
2 Department of Life and Reproduction, Section of Biochemistry, University of Verona, 37134 Verona, Italy
3 Department of Biomedical Science, University of Sassari, 07100 Sassari, Italy
4 Department of Oncology, University of Torino, 10010 Torino, Italy

Correspondence should be addressed to Lucia De Franceschi; lucia.defranceschi@univr.it

Received 28 February 2013; Accepted 4 June 2013

Academic Editor: József Balla

Copyright © 2013 Lucia De Franceschi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

\( \beta \)-thalassemia is a worldwide distributed monogenic red cell disorder, characterized by the absence or reduced \( \beta \)-globin chain synthesis. Despite the extensive knowledge of the molecular defects causing \( \beta \)-thalassemia, less is known about the mechanisms responsible for the associated ineffective erythropoiesis and reduced red cell survival, which sustain anemia of \( \beta \)-thalassemia.[5].

\( \beta \)-thalassemic red cells are characterized by extended red cell membrane oxidative damage related to the excess of unpaired chains, resulting in coclustering of denatured globin and band 3 protein with the generation of large membrane aggregates.

1. Introduction

The World Health Organization has identified the hereditary red cell disorders as emerging diseases with high impact on public health systems in both Western and developing countries. Approximately 7% of the global population is carrier of such disorders, and 300,000–400,000 babies with severe forms of these diseases are born each year [1–3]. Severe hereditary hemoglobin disorders of red cells occur at highest frequency in tropical regions, but population migrations have ensured that they are present and growing in prevalence in most Western countries. Hemoglobinopathies constitute the single most common monogenic defect worldwide, and among hemoglobin disorders, the thalassemias prominently contribute to [1–4]. \( \beta \)-thalassemias (\( \beta \)-thal) are characterized by the presence of mutations on beta-globin gene resulting in the absence or reduced synthesis of \( \beta \)-globin chains. This is responsible for unbalance in globin chain synthesis with unpaired \( \alpha \)-chains aggregation. Despite the extensive knowledge of the molecular defects causing \( \beta \)-thalassemia, less is known about the mechanisms responsible for the associated ineffective erythropoiesis and reduced red cell survival, which sustain anemia of \( \beta \)-thalassemia [5].

2. \( \beta \)-Thalassemic Red Cells and Oxidative Stress

\( \beta \)-thalassemic red cells are characterized by extensive red cell membrane oxidative damage related to the excess of unpaired chains, resulting in coclustering of denatured globin and band 3 protein with the generation of large membrane aggregates.
of band 3 tyrosine phosphorylation in anchoring of the membrane cytoskeleton to the lipid bilayer [16–18]. This function is linked specifically to its association with adducin and ankyrin in two distinct junctional complexes [19]. Rupture of either of these two bridges yields an erythrocyte that spontaneously loses membrane surface through vesiculation/blebbing. Recent studies from our lab demonstrate that Syk-mediated tyrosine phosphorylation of oxidatively modified band 3 leads to complete inhibition of ankyrin binding and the consequent dissociation of band 3 from the cytoskeleton [20]. When red cells are mechanically stressed, they bleb membrane surface and vesiculate. Indeed, in scrutinizing the literature, we have noted that membrane vesiculation and release of circulating microparticles (MPs) constitute a common characteristic of erythrocyte pathologies (sickle cell disease, G6PDH deficiency, β-thalassemia) that are characterized by elevated band 3 tyrosine phosphorylation. A study showed significantly higher levels of circulating MPs originating from red cell membranes in β-thalassemia intermedia patients compared to controls, especially in splenectomized patients [21]. MPs originating from red cell membranes are also considered a major cause of premature atherosclerosis described in thalassemia intermedia patients [22].

Band 3 tyrosine phosphorylation observed in β-thalassemia may impact additional erythrocyte functions. Band 3 organizes a complex of glycolytic enzymes on the membrane and thereby controls the flux of glucose between the pentose phosphate pathway (PPP) and glycolysis. Phosphorylation of band 3 by Syk leads to displacement of these glycolytic enzymes from an inhibitory site on band 3, resulting in

---

**Figure 1**: Schematic diagram of abnormalities observed in β-thalassemic red cells. The presence of pathological free iron (Fe) close to the membrane is involved in the Fenton reaction producing reactive oxygen species (ROS, \( \cdot O_2^- \)) contributing to the prooxidant environment of β-thalassemic red cells. The unbalance in α/β chain synthesis results in aggregation of highly oxidative α chains. The prooxidant environment is responsible for protein and lipid oxidative damage favoring abnormal clusterization of red cell membrane proteins such as band 3, promoting band 3 tyrosine phosphorylation (P) and exposure of phosphatidylserine (PS). The abnormally clustered band 3 is recognized by naturally occurring anti-band 3 antibody (IgG). The severely damaged β-thalassemic red cells released microparticles (MPs). The β-thalassemic red cells have short lifespan and are removed by macrophages of the reticuloendothelial systems through PS exposure and IgG anti-band 3 mediated mechanisms. The oxidative stress abnormally activates the K–Cl cotransport (KCC), which promotes \( \mathbf{K}^+ \), \( \mathbf{Cl}^- \), and water loss contributing to the reduced red cell \( \mathbf{K}^+ \) content that characterizes β-thalassemic red cells.
activation of glycolysis and a decline in red cell reducing power through NADPH production [23].

Several lines of evidence indicate that in thalassemias and in unstable hemoglobin diseases, damaged red cells are removed by spleen through an immunological mechanism [6, 24]. High amounts of anti-band 3 antibodies (NAbs) and C3b are constantly found bound to band 3-hemichromes aggregates [6], leading to intense phagocytosis. Those high molecular weight complexes containing IgG and C3b were isolated from red cell membranes in thalassemic, sickle cell, and haemoglobin C patients [25, 26]. The colocalization of the various components was also demonstrated by fluorescence microscopy [26]. Interestingly, anti-band 3 NAbs eluted from thalassemic red cells recognize dimeric/oxidized band 3 [6]. In thalassemias, a correlation has been found between the degree of anemia and the amount of anti-band 3 NAbs and of band 3/hemichrome copolymer in red cell membranes indicating a central role of NAbs in β-thal red cells removal [24]. In conclusion, the most relevant membrane changes linked to hemolysis and complications in thalassemias appear to deal with the binding of naturally occurring antibodies and with the destabilization of the red cell membrane leading to membrane loss and microparticle release.

3. The Membrane Oxidative Damage Participates to the Removal of β-Thal Red Cells by the Macrophage System:
The Connection with Malaria Infection

Previous studies indicate a major role of immune determinants in the removal of β thalassemic red cells [24]. The interactions between thalassemic red cells and plasmodia appear to play a major role in natural and acquired protection to malaria. Heterozygous α- and β-thalassemias are extremely frequent in malaria endemic areas displaying a well-balanced hematological situation [27], while there is a widespread consensus that thalassemias determine an efficient resistance to severe malaria [28]. In particular, α-thalassemias are the most common mutation in malaria endemic regions and are considered to confer protection against clinical manifestations related to both severe forms [29–32] or uncomplicated malaria [33]. Although the molecular basis of the mechanism of resistance is not completely understood it has been observed that α-thalassemic red cells infected with Plasmodium falciparum bind higher amounts of antibodies or complement factors from immune sera [34, 35]. Moreover, lower levels of the complement receptor-1 (CRI) have been found in α-thalassemic red cells, and a reduction of infected red cells to form rosettes (associated to severe malaria) has been associated to CRI deficiency [36].

Heterozygous β-thalassemia also confers protection against severe malaria and uncomplicated malaria in children [35, 37]. One study indicates that heterozygous β-thalassemic red cells are unable to sustain the normal development of Plasmodium falciparum in vitro” [38]. In addition, similarly to α-thalassemia, immunological determinants appear to be involved in a more efficient recognition of infected β-thalassemic red cells [34, 39]. More recently it has been observed that both heterozygous α- and β-thalassemic red cells do not apparently damage the parasites but induce a loss of viability of the infected erythrocytes and their removal by macrophages [40]. We have also observed that the deletion of 11 amino acids at the band 3 amino terminal (band 3 Neapolis) results in a profound red cell membrane destabilization, in increasing naturally occurring IgG binding, and a reduction of P. falciparum to grow in these red cells [41]. These findings suggest that different mutations, including Southeast Asian ovalocytosis, elliptocytosis, and unstable hemoglobins affecting structure, functions, and antigenic properties of the red cell membrane, might interfere with the development of malaria parasites [42–44].

In that respect, several studies have identified proteins that are phosphorylated upon malarial infection [41, 45–47]. Band 3 represents the earliest tyrosine phosphorylation event during parasite development, beginning at low levels during early ring stage parasitemia and increasing continuously until parasite egress [48]. We have recently shown that in red cells from heterozygous β-thalassemic subjects the process of band 3 phosphorylation is amplified [16], suggesting that band 3 related destabilization of the host red cell membrane may be involved in the mechanism of malaria resistance. In support to this hypothesis, recent data demonstrated that long-lived radicals, indolone-N-oxide derivatives (INODs), exert antiplasmodial activity in the low nanomolar range accelerating the rate of phosphorylation of band 3, its clustering, and altering the stability of the erythrocyte membrane without a direct effect on parasite targets [49]. The relationships between band 3 phosphorylation, its clustering, and the binding of naturally occurring antibodies in malaria and thalassemias remain to be fully established [50].

4. β-Thalassemia Red Cells Abnormal Activation of K–Cl Cotransport with K+ Loss Related to the Membrane Oxidative Damage

The observation of the relationship between hemoglobin precipitation and reduced cell K+ content in β-thal erythrocytes has suggested a link between red cell membrane oxidative damage and abnormalities of red cell membrane ion transport pathways in β-thal red cells [51, 52]. In vitro studies with oxidant agents mimicking β-thal red cell membrane damage as phenylhydrazine (PHZ) have helped in dissecting the contribution of the oxidative stress in activation of different membrane ion transport pathways involved in generation of red cell with reduced K+ content such as in β-thalassemia [51, 52]. The red cell membrane transport can be divided into (i) the energy driven systems as the Na–K ATPase pump; (ii) the gradient driven systems as the Na–K–2Cl cotransport and the K–Cl cotransport; (iii) the exchange as the Na–H or the Na–Li exchange; and (v) the channel as the Gardos channel [52–59]. In β-thal red cells we have shown that the activity of the K–Cl cotransport (KCC) is increased, and its abnormal activation is related to the severe membrane oxidative damage characterizing β-thal erythrocytes [51, 52] (Figure 1). When β-thal red cells are treated with DIOA
impact of AHSP deficiency in β-thalassemia patients treated with Mg-pidolate (1.2 mEq/Kg/d), increase the red cell K\(^{2+}\) content, which characterized by reduced red cell Mg\(^{2+}\) content. The development of animal models for β-thalassemia have shown that the activation of K–Cl cotransport might also be increased by reduced red cell Mg\(^{2+}\) content, which characterized by Mg-reduction in K–Cl cotransport activity, increase of red cell K\(^{2+}\) content, and decrease of reticulocyte count [63]. These data suggest that modulation of K–Cl cotransport through different strategies ameliorates the hematological phenotype of β-thalassemia.

**5. Novel Cytoprotective Systems and β-Thalassemia**

Although β-thal red cells have been largely studied in the last decades and the contribution of the oxidative stress has been documented in shortening β-thal red cell lifespan, the role of reactive oxygen species (ROS) in ineffective erythropoiesis of β-thalassemia has been only partially investigated.

Previous studies have identified a small protein stabilizing the α chains (AHSP, α hemoglobin-stabilizing protein) as an important protein facilitating hemoglobin assembly and partially protecting the erythroid precursors from the α chain excess (Figure 2). In fact, AHSP binds free α-globin chains, stabilizing their structure and prevents their precipitation [77–80]. Indeed, anemia of β-thalassemic mice is more severe in β-thalassemic/AHSP-deficient mice [77–79]. However, the impact of AHSP deficiency in β-thalassemia patients is still under evaluation and the link between decreased AHSP expression and severity of β-thalassemic syndromes remains speculative [79].

Another protective factor in β-thalassemic erythropoiesis is the heme-regulated inhibitor of protein translation (HRI) that represses globin translation in heme-deficient erythroid precursors [81] (Figure 2). HRI is the heme-regulated eIF2α kinase that phosphorylates a subunit of eIF2, a crucial regulatory translational initiating factor. Studies in in vitro systems have shown that the activation of HRI involves also ROS and requires the molecular chaperones heat shock proteins 70 and 90 (HSP70 and -90) [82]. Thus, β-thalassemic erythropoiesis characterized by ROS and unbalance of globin chain synthesis might be an interesting model to validate the role of HRI-eIF2α pathway. In fact, β-thal mice genetically lacking HRI show a more severe hematological phenotype compared to β-thal mice, supporting the key role of eIF2α in stress erythropoiesis [81, 83]. Recently, HRI-dependent eIF2αP has been also shown to enhance the translation of the Atf4 in mouse erythroid cell precursors exposed to oxidative stress [81, 84]. This results in upregulation of genes from antioxidant systems such as heme-oxygenase-1 (ho-1), glutathione S-transferase-μ (gsts), and NAD(P)H quinone oxidoreductase 1 (Nqo1). In β-thal erythroid precursors the increase of eIF2α-P by salubrinal treatment results in inhibition of globin chain synthesis, suggesting that pharmacological modulation of eIF2α-P might possibly impact the β-thal ineffective erythropoiesis through inhibition of globin chain synthesis and possibly through upregulation of antioxidant systems (Figure 2).

Another novel cytoprotective system recently described in β-thalassemia is peroxiredoxin-2 (PRDX2) (Figure 2). PRDX2 is a typical 2-cysteine (Cys51 and -172) peroxiredoxin, which acts as antioxidant and molecular chaperone in different cell types [85, 86].

**5.1. Peroxiredoxin-2 and β-Thalassemia.** PRDX2 is the third most abundant cytoplasmic protein in red cells and is able to reduce and detoxify a vast range of organic peroxides, H\(_2\)O\(_2\), and peroxynitrite [87, 88]. Recently, we have shown that PRDX2 expression is increased in a mouse model for β-thalassemia [65, 89]. However, PRDX2 membrane translocation in β-thal red cells is reduced despite the severe membrane oxidative damage. Since β-thal red cells are characterized by the presence of hemichrome membrane association, we have shown that PRDX2 is displaced by the membrane in function of the proportion of denaturated and oxidized hemoglobin recovered on the membrane as hemichromes [89]. Thus, in β-thal red cells PRDX2 is unable to translocate to the membrane in response to oxidative damage since hemichromes mask PRDX2 binding site on the membrane. Based on the evidences that band 3 is the docking site for hemichrome on the red cell membrane [6, 41], we hypothesize that band 3 might be the binding site also for PRDX2. To address this question we have studied the interactions of recombinant PRDX2 with the cytoplasmic domain of band 3 [90]. We show that PRDX2 binds to the cytoplasmic domain of band 3 with different experimental methodological approaches including cross-linking studies, fluorescence and dichroic measurements, surface plasmon
Oxidative Medicine and Cellular Longevity

In β-thalassemic erythropoiesis the radical oxidative species (ROS) induces peroxiredoxin-2 (PRDX2) expression. In the early stage of β-thalassemic erythropoiesis, ROS and heme levels are both increased and PRDX2 acts on both targets; in more mature cells, when ROS levels are still high and heme levels are reduced, ROS might become the PRDX2 major target (see text for details). ROS promotes HRI activation, which requires the heat shock proteins 70 and 90 (HSP70, -90). HRI activation results in phosphorylation of the α-subunit of eIF2, an important regulatory translation initiating factor, which inhibits the α-β-globin chain synthesis and activates the Atf4 pathway towards redox genes such as heme-oxygenase-1 (ho-1), glutathione S-transferase (gst), and NAD(P)H quinone oxidoreductase 1 (Nqo1). The upregulation of these genes in combination with the decrease in α-β-globin chain synthesis might beneficially affect the ineffective erythropoiesis of β-thalassemia. The α chains (AHSP, α hemoglobin-stabilizing protein) is another cytoprotective system, which partially protects the erythroid precursors from the α chain excess. AHSP binds free α-globin chains, stabilizing their structure. AHSP prevents their precipitation and might be important in β-thalassemic erythropoiesis characterized by unbalance in globin chain synthesis.

Looking for novel cytoprotective mechanisms in β-thal erythropoiesis we have carried out a classic proteomic analysis of erythroid precursors from healthy and β-thal intermedia subjects. We identify PRDX2 as one of the antioxidant systems differently expressed during erythroid maturation in β-thal erythroid cells compared to controls [91]. In other cell types PRDX2 has been demonstrated to be induced by oxidative stress and that cells overexpressing PRDX2 are more resistant to the oxidative stress [92, 93]. To evaluate the impact of PRDX2 during erythropoiesis in cells, exposed in vitro to oxidative stress, we silenced PRDX2 in K562 cells and we observed decreased differentiation and reduced cell survival, supporting the important role of PRDX2 as cytoprotective system during stress erythropoiesis [91]. Since PRDX2 is highly expressed during β-thal erythropoiesis, we speculate that its role might not be limited to antioxidant function. Using recombinant PRDX2 we demonstrate that PRDX2 specifically binds heme with decreased PRDX2 peroxidase activity. In β-thal erythropoiesis we propose that in early β-thal erythroid precursors, characterized by high levels of ROS and heme, PRDX2 targets both ROS and heme to reduce oxidative stress. While in late β-thal erythropoiesis, when ROS levels are still high but heme levels are reduced, ROS might be the major target of PRDX2 (Figure 2) [91]. Future studies using sorted erythroid precursors at different

Figure 2: Schematic model of novel cytoprotective mechanisms in response to oxidative stress in β-thalassemic (β-thal) erythroid precursors. In β-thalassemic erythropoiesis the radical oxidative species (ROS) induces peroxiredoxin-2 (PRDX2) expression. In the early stage of β-thalassemic erythropoiesis, ROS and heme levels are both increased and PRDX2 acts on both targets; in more mature cells, when ROS levels are still high and heme levels are reduced, ROS might become the PRDX2 major target (see text for details). ROS promotes HRI activation, which requires the heat shock proteins 70 and 90 (HSP70, -90). HRI activation results in phosphorylation of the α-subunit of eIF2, an important regulatory translation initiating factor, which inhibits the α-β-globin chain synthesis and activates the Atf4 pathway towards redox genes such as heme-oxygenase-1 (ho-1), glutathione S-transferase (gst), and NAD(P)H quinone oxidoreductase 1 (Nqo1). The upregulation of these genes in combination with the decrease in α-β-globin chain synthesis might beneficially affect the ineffective erythropoiesis of β-thalassemia. The α chains (AHSP, α hemoglobin-stabilizing protein) is another cytoprotective system, which partially protects the erythroid precursors from the α chain excess. AHSP binds free α-globin chains, stabilizing their structure. AHSP prevents their precipitation and might be important in β-thalassemic erythropoiesis characterized by unbalance in globin chain synthesis.

resonance analysis, and proteolytic digestion assay. This finding is also supported by the absence of PRDX2 membrane association in a patient with band 3 Neapolis, a truncated isoform of band 3 lacking the N-terminal 11 amino acid residues [41, 90]. We believe that the membrane association of PRDX2 with band 3 might be important in protecting band 3 from oxidative damage and its associated membrane proteins. In the context of β-thal red cells the presence of hemichrome masking the docking site for PRDX2 contributes to further amplification of red cell membrane oxidative damage characterizing β-thalassemic erythrocytes.

Future studies using sorted erythroid precursors at different
Table 1: Effects of different antioxidant treatments in β thalassemia.

| Molecule   | Model                                      | Evidences                                                                                                     | Ref. |
|------------|--------------------------------------------|----------------------------------------------------------------------------------------------------------------|------|
| Vitamin E  | β-thal intermedia patients (in vivo study) | ↓ MDA, Amelioration in the oxidation of low density lipoproteins, Amelioration of RBCs osmotic fragility, No changes in transfusion requirement | [70–72] |
| Curcumin   | β-thal patients (in vitro study)           | ↓ lipid peroxidation, ↓ methemoglobin, but no changes in Hb levels                                             | [73, 74] |
|            | β-thal/βHbE patients (in vivo study)       | ↓ ROS, ↑ GSH                                                                                                   |      |
| FPP        | β-thal/βHbE patients (in vivo)              | ↓ PS positive RBCs, ↓ RBCs phagocytosis, No effects on Hb levels                                               | [73, 75] |
|            | β-thal major and intermedia patients       | ↑ RBCs K+ content, ↓ KCl cotransport activity, ↓ PS positive RBCs, ↑ RBCs membrane and plasma vitamin E levels   |      |
|            | (in vitro study)                           | Amelioration of β-thal mouse erythropoiesis                                                                  | [66] |
| MonoHER    | β-thal mouse model (in vivo)               | ↑ PS positive RBCs, ↑ RBCs phagocytosis, No effects on Hb levels                                               | [76] |
| AD4        | β-thal major and intermedia patients       | ↑ ROS, ↑ GSH                                                                                                   |      |
|            | (in vitro study)                           | ↓ PS positive RBCs, ↓ RBCs phagocytosis, No effects on Hb levels                                               | [76] |
|            | β-thal mouse model (in vivo)               |                                                                                                                |      |

β-thal: β-thalassemia; MDA: malondialdehyde; RBC: red blood cell; Hb: hemoglobin; PS: phosphatidylserine; GSH: reduced glutathione peroxidase; ROS: reactive oxygen species; FPP: fermented papaya preparation; AD4: N-acetylcysteine amide.

stage of maturation [94] need to be carried out to better characterize the role of PRDX2 in β-thal erythropoiesis.

6. Antioxidants as Therapeutic Strategy in β-Thalassemia

Since the oxidative stress plays a key role in the pathogenesis of β-thalassemia, the use of various molecules with antioxidant properties as possible therapeutic strategy in β-thalassemia has been explored (Table 1). A pilot trial with large dose of oral vitamin E, prompted by the abnormally low levels of this vitamin in plasma of patients with β-thal intermedia, showed a decrease in the levels of malonylaldehyde but not in transfusion requirements [70, 73]. Amelioration of β-thal red cell osmotic fragility has been also reported in β-thal major patients treated with vitamin E supplementation [71]. In another study with vitamin E supplementation involving β-thal intermedia patients, an improvement of plasma oxidative stress has been reported, supporting the role of vitamin E as antioxidant agent with multitarget effects in β-thalassemia [72]. The polyphenol curcumin caused a significant inhibition of lipid peroxidation in β-thal red cell ghosts [73] and an improvement in methemoglobin levels in β-thal patients treated with curcumin, with no effects on patients hemoglobin levels [74].

Another antioxidant molecule that has been evaluated in β-thalassemia is the fermented papaya preparation (FPP). Studies in vitro and in vivo in both mouse model for β-thalassemia and β-thal human subjects have shown that FPP reduces the β-thal red cell oxidative stress, the membrane lipid peroxidation, and the percentage of PS positive red cells, and increases reduced glutathione (GSH). The amelioration of red cell features induced by FPP is also associated with reduced red cell phagocytic index, suggesting possible reduction in removal of FPP treated β-thal red cells from the peripheral circulation by the macrophage system [73, 76]. Recently, in a mouse model for β-thal it was shown that a novel semisynthetic flavanoid, 7-monohydroxyethylrutoside (monoHER), reduces the percentage of PS positive red cells, increases the red cell membrane and plasma vitamin E content and red cell K+ content with beneficial effects on mouse β-thal erythropoiesis [66]. The thiol compound N-acetylcysteine amide (AD4), the amide form of N-acetyl cysteine (NAC), has been studied both in vitro in β-thal red cells and in vivo in mouse model for β-thalassemia [75]. Amer et al. show that in β-thal mouse red cells in vitro
and in vivo AD4 significantly improves GSH levels and reduces the percentage of PS positive cells and the β-thal phagocytic index, suggesting that the restoration of thiol levels in β-thal red cells might represent an additional strategy to antioxidant treatment in β-thalassemia. In a mouse model for β-thalassemia we have recently shown that resveratrol, a polyphenolic-stilbene, ameliorates the β-thal ineffective erythropoiesis through the activation of FOXO3, transcriptional factor, and reduces the oxidative stress in circulating β-thal red cells [95].

7. Future Prospective

In conclusion, the oxidative stress plays a central role in the pathogenesis of anemia in β-thalassemia. The emerging picture for treatment of β-thalassemia is that abnormalities ranging from red cell membrane proteins structure and function and membrane ion transport pathways to novel cytoprotective systems in erythropoiesis might constitute new pharmacological targets for treating β-thalassemia. Future studies should be designed to evaluate in vivo novel antioxidant strategies with multitarget effects on both mature β-thal red cells and erythropoiesis with the final goal to impact anemia of β-thalassemia.

Acknowledgments

This work was supported by grants from FUR2011-2012, University of Verona, to Mariarita Bertoldi and Lucia De Franceschi and by AITED (Associazione Italiana Talassemie e Drenapanociti) to Lucia De Franceschi.

References

[1] D. J. Weatherall, “The global problem of genetic disease,” Annals of Human Biology, vol. 32, no. 2, pp. 117–122, 2005.
[2] D. J. Weatherall and J. B. Clegg, “Inherited haemoglobin disorders: an increasing global health problem,” Bulletin of the World Health Organization, vol. 79, no. 8, pp. 704–712, 2001.
[3] B. Modell and M. Darlison, “Global epidemiology of haemoglobin disorders and derived service indicators,” Bulletin of the World Health Organization, vol. 86, no. 6, pp. 480–487, 2008.
[4] L. de Franceschi, M. D. Cappellini, and O. Olivieri, “Thrombosis and sickle cell disease,” Seminars in Thrombosis and Hemostasis, vol. 37, no. 3, pp. 226–236, 2011.
[5] D. Rund and E. Rachmilewitz, “Beta-thalassemia,” The New England Journal of Medicine, vol. 353, no. 11, pp. 1135–1146, 2005.
[6] F. Mannu, P. Arrese, M. D. Cappellini et al., “Role of hemichrome binding to erythrocyte membrane in the generation of band-3 alterations in β-thalassemia intermedia erythrocytes,” Blood, vol. 86, no. 5, pp. 2014–2020, 1995.
[7] E. Shinar and E. A. Rachmilewitz, “Oxidative denaturation of red blood cells in thalassemia,” Seminars in Hematology, vol. 27, no. 1, pp. 70–82, 1990.
[8] T. Repka, O. Shaley, R. Reddy et al., “Nonrandom association of free iron with membranes of sickle and β-thalassemic erythrocytes,” Blood, vol. 82, no. 10, pp. 3204–3210, 1993.
[9] S. L. Schrier and N. Mohandas, “Globin-chain specificity of oxidation-induced changes in red blood cell membrane properties,” Blood, vol. 79, no. 6, pp. 1586–1592, 1992.
[10] L. de Franceschi, O. Shaley, A. Piga et al., “Deferiprone therapy in homozygous human β-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity,” Journal of Laboratory and Clinical Medicine, vol. 133, no. 1, pp. 64–69, 1999.
[11] A. Pantaleo, E. Ferru, G. Giribaldi et al., “Oxidized and poorly glycosylated band 3 is selectively phosphorylated by Syk kinase to form large membrane clusters in normal and G6PD-deficient red blood cells,” Biochemical Journal, vol. 418, no. 2, pp. 359–367, 2009.
[12] L. de Franceschi, A. Biondani, F. Carta et al., “PTPepsilon has a critical role in signaling transduction pathways and phosphoprotein network topology in red cells,” Proteomics, vol. 8, no. 22, pp. 4695–4708, 2008.
[13] M. D. Scott, J. J. van den Berg, T. Repka et al., “Effect of excess alpha-hemoglobin chains on cellular and membrane oxidation in model beta-thalassemic erythrocytes,” Journal of Clinical Investigation, vol. 91, no. 4, pp. 1706–1712, 1993.
[14] L. de Franceschi, C. Tomelleri, A. Matte et al., “Erythrocyte membrane changes of chorea-acanthocytosis are the result of altered Lyn kinase activity,” Blood, vol. 118, no. 20, pp. 5652–5663, 2011.
[15] E. Shinar, E. A. Rachmilewitz, and S. E. Lux, “Differing erythrocyte membrane skeletal protein defects in alpha and beta thalassemia,” Journal of Clinical Investigation, vol. 83, no. 2, pp. 404–410, 1989.
[16] A. Pantaleo, L. de Franceschi, E. Ferru, R. Vono, and F. Turrini, “Current knowledge about the functional roles of phosphorylative changes of membrane proteins in normal and diseased red cells,” Journal of Proteomics, vol. 73, no. 3, pp. 445–455, 2010.
[17] A. Siciliano, F. Turrini, M. Bertoldi et al., “Deoxygenation affects tyrosine phosphoproteome of red cell membrane from patients with sickle cell disease,” Blood Cells, Molecules, and Diseases, vol. 44, no. 4, pp. 233–242, 2010.
[18] A. Iolascon, L. De Falco, F. Borgese et al., “A novel erythroid anion exchange variant (Gly796Arg) of hereditary stomatocytosis associated with dyserythropoiesis,” Haematologica, vol. 94, no. 8, pp. 1049–1059, 2009.
[19] N. Mohandas and X. An, “New insights into function of red cell membrane proteins and their interaction with spectrin-based membrane skeleton,” Transfusion Clinique et Biologique, vol. 13, no. 1–2, pp. 29–30, 2006.
[20] E. Ferru, K. Giger, A. Pantaleo et al., “Regulation of membrane-cytoskeletal interactions by tyrosine phosphorylation of erythrocyte band 3,” Blood, vol. 117, no. 22, pp. 5998–6006, 2011.
[21] M. Westerman, A. Pizzey, J. Hirschman et al., “Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy,” The British Journal of Haematology, vol. 142, no. 1, pp. 126–135, 2008.
[22] G. Hahalis, A. Kalogeropoulos, G. Terzis et al., “Premature atherosclerosis in non-transfusion-dependent β-thalassemia intermedia,” Cardiology, vol. 118, no. 3, pp. 159–163, 2011.
[23] M. L. Harrison, P. Rathinavelu, P. Arrese, R. L. Geahlen, and P. S. Low, “Role of band 3 tyrosine phosphorylation in the regulation of erythrocyte glycolysis,” Journal of Biological Chemistry, vol. 266, no. 7, pp. 4106–4111, 1991.
[24] M. D. Cappellini, D. Tavazzi, L. Duca et al., “Metabolic indicators of oxidative stress correlate with haemichrome attachment to membrane, band 3 aggregation and erythropoagocytosis in β-thalassaemia intermedia,” The British Journal of Haematology, vol. 104, no. 3, pp. 504–512, 1999.
[25] P. S. Low, “Structure and function of the cytoplasmic domain of band 3: center of erythrocyte membrane-peripheral protein interactions,” Biochimica et Biophysica Acta, vol. 864, no. 2, pp. 145–167, 1986.
[26] F. Tokumasu, R. M. Fairhurst, G. R. Oster et al., “Band 3 modifications in Plasmodium falciparum-infected AA and CC erythrocytes assayed by autocorrelation analysis using quantum dots,” Journal of Cell Science, vol. 118, no. 5, pp. 1091–1098, 2005.
[27] F. J. I. Fowkes, S. J. Allen, A. Allen, M. P. Alpers, D. J. Weatherall, and K. P. Day, “Increased microerythrocyte count in homozygous α-thalassaemia contributes to protection against severe malarial anaemia,” PLoS Medicine, vol. 5, no. 3, article e56, pp. 0494–0501, 2008.
[28] C. López, C. Saravia, A. Gomez, J. Hoebeke, and M. A. Patarroyo, “Mechanisms of genetically-based resistance to malaria,” Gene, vol. 467, no. 1-2, pp. 1–12, 2010.
[29] T. N. Williams, K. Maitland, S. Bennett et al., “High incidence of malaria in α-thalassaemic children,” Nature, vol. 383, no. 6600, pp. 522–525, 1996.
[30] S. J. Allen, O. Donnell A. N. D. Alexander et al., “α+--Thalassaemia protects children against disease caused by other infections as well as malaria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 26, pp. 14736–14741, 1997.
[31] F. P. Mockenhaupt, S. Ehrhardt, S. Gellert et al., “α-thalassaemia protects African children from severe malaria,” Blood, vol. 104, no. 7, pp. 2003–2006, 2004.
[32] S. Wambua, T. W. Mwangi, M. Kortok et al., “The effect of α-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya,” PLoS Medicine, vol. 3, no. 5, article e158, 2006.
[33] A. Enevold, J. P. Lusingu, B. Mmbando et al., “Reduced risk of uncomplicated malaria episodes in children with alpha +--thalassemia in Northeastern Tanzania,” The American Journal of Tropical Medicine and Hygiene, vol. 78, no. 5, pp. 714–720, 2008.
[34] G. A. Luzzi, A. H. Merry, C. I. Newbold, K. Marsh, and G. Pasvol, “Protection by α-thalassaemia against Plasmodium falciparum malaria: modified surface antigen expression rather than impaired growth or cytoadherence,” Immunology Letters, vol. 30, no. 2, pp. 233–240, 1991.
[35] Y. Yuthavong and P. Wilairat, “Protection against malaria by thalassaemia and haemoglobin variants,” Parasitology Today, vol. 9, no. 7, pp. 241–245, 1993.
[36] I. A. Cockburn, M. J. Mackinnon, A. O’Donnell et al., “A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 1, pp. 272–277, 2004.
[37] M. Willcox, A. Bjorkman, and J. Brohult, “Falciparum malaria,” Kain, “Innate immunity to malaria caused by Plasmodium falciparum,” Clinical and Investigative Medicine, vol. 25, no. 6, pp. 262–272, 2002.
[38] K. Ayi, F. Turrini, A. Piga, and P. Arese, “Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassaemia trait,” Blood, vol. 104, no. 10, pp. 3364–3371, 2004.
[39] S. Perrotta, A. Borriello, A. Scaloni et al., “The N-terminal II amino acids of human erythrocyte band 3 are critical for aldolase binding and protein phosphorylation: implications for band 3 function,” Blood, vol. 106, no. 13, pp. 4359–4366, 2005.
[40] B. Genton, F. Al-Yaman, C. S. Mgone et al., “Ovalocytosis and cerebral malaria,” Nature, vol. 378, no. 6557, pp. 564–565, 1995.
[41] S. J. Allen, A. O’Donnell, N. D. E. Alexander et al., “Prevention of cerebral malaria in children in Papua New Guinea by Southeast Asian ovalocytosis band 3,” The American Journal of Tropical Medicine and Hygiene, vol. 60, no. 6, pp. 1056–1060, 1999.
[42] T. N. Williams, “Red blood cell defects and malaria,” Molecular and Biochemical Parasitology, vol. 149, no. 2, pp. 121–127, 2006.
[43] M. C. Murray and M. E. Perkins, “Phosphorylation of erythrocyte membrane and cytoskeleton proteins in cells infected with Plasmodium falciparum,” Molecular and Biochemical Parasitology, vol. 34, no. 3, pp. 229–236, 1989.
[44] C. Magowan, J. Liang, J. Yeung, Y. Takakuwa, R. L. Coppel, and N. Mohandas, “Plasmodium falciparum: influence of malarial and host erythrocyte skeletal protein interactions on phosphorylation in infected erythrocytes,” Experimental Parasitology, vol. 89, no. 1, pp. 40–49, 1998.
[45] B. W. Sutterlin, B. Kappes, and R. M. Franklin, “Localization and stage specific phosphorylation of Plasmodium falciparum phosphoproteins during the intraerythrocytic cycle,” Molecular and Biochemical Parasitology, vol. 46, no. 1, pp. 113–122, 1991.
[46] A. Pantaleo, E. Ferru, F. Carta et al., “Analysis of changes in tyrosine and serine phosphorylation of red cell membrane proteins induced by P. falciparum growth,” Proteomics, vol. 10, no. 19, pp. 3469–3479, 2010.
[47] A. Pantaleo, E. Ferru, R. Vono et al., “New antimalarial indolone-N-oxides, generating radical species, destabilize the host cell membrane at early stages of Plasmodium falciparum growth: role of band 3 tyrosine phosphorylation,” Free Radical Biology and Medicine, vol. 52, no. 2, pp. 527–536, 2012.
[48] A. Pantaleo, G. Giribaldi, F. Mannu, P. Arese, and F. Turrini, “Naturally occurring anti-band 3 antibodies and red blood cell removal under physiological and pathological conditions,” Autoimmunity Reviews, vol. 7, no. 6, pp. 457–462, 2008.
[49] O. Olivieri, L. de Franceschi, M. D. Capellini, D. Girelli, R. Corrocher, and C. Brugnara, “Oxidative damage and erythrocyte membrane transport abnormalities in thalassemias,” Blood, vol. 84, no. 1, pp. 315–320, 1994.
[50] L. de Franceschi, L. Ronzoni, M. D. Capellini et al., “K-Cl cotransport plays an important role in normal and β thalassemic erythropoiesis,” Haematologica, vol. 92, no. 10, pp. 1319–1326, 2007.
[51] C. Brugnara and L. de Franceschi, “Effect of cell age and phenylhydrzone on the cation transport properties of rabbit erythrocytes,” Journal of Cellular Physiology, vol. 154, no. 2, pp. 271–280, 1993.
[52] W. Su, B. E. Shmukler, M. N. Chernova et al., “Mouse K-Cl cotransporter KCC1: cloning, mapping, pathological expression, and functional regulation,” The American Journal of Physiology, vol. 277, no. 5, pp. C899–C912, 1999.
[53] L. de Franceschi, F. Turrini, E. M. Del Giudice et al., “Decreased band 3 anion transport activity and band 3 clusterization in congenital dyserythropoietic anaemia type II,” Experimental Hematology, vol. 26, no. 9, pp. 869–873, 1998.
[56] L. de Franceschi, O. Olivieri, E. Miraglia del Giudice et al., “Membrane cation and anion transport activities in erythrocytes of hereditary spherocytosis: effects of different membrane protein defects,” *American Journal of Hematology*, vol. 55, no. 3, pp. 121–128, 1997.

[57] L. de Franceschi, R. S. Franco, M. Bertoldi et al., “Pharmacological inhibition of calpain-1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease,” *FASEB Journal*, vol. 27, no. 2, pp. 750–759, 2013.

[58] L. de Franceschi, N. Saadane, M. Trudel, S. L. Alper, C. Brugnara, and Y. Beuzard, “Treatment with oral clotrimazole blocks Ca²⁺-activated K⁺ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease,” *Journal of Clinical Investigation*, vol. 93, no. 4, pp. 1670–1676, 1994.

[59] A. Wieschhaus, A. Khan, A. Zaidi et al., “Calpain-1 knockout reveals broad effects on erythrocyte deformability and physiology,” *The Biochemical Journal*, vol. 448, no. 1, pp. 141–152, 2012.

[60] L. de Franceschi, F. Turrini, O. Olivieri, R. Corrocher, C. A. Lowell, and G. Berton, “Deficiency of Sfc family kinases Fgr and Hck results in activation of erythrocyte K/Cl cotransport,” *Journal of Clinical Investigation*, vol. 99, no. 2, pp. 220–227, 1997.

[61] L. de Franceschi et al., “Dietary magnesium supplementation reduces pain crises in patients with sickle cell disease,” *Blood*, vol. 90, 1997.

[62] L. de Franceschi, P. Rouyer-Fessard, S. L. Alper, H. Jouault, C. Brugnara, and Y. Beuzard, “Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a β-thalassemic mouse: a model for human therapy,” *Blood*, vol. 87, no. 3, pp. 1188–1195, 1996.

[63] L. de Franceschi, M. D. Cappellini, G. Graziadei et al., “The effect of dietary magnesium supplementation on the cellular abnormalities of erythrocytes in patients with β-thalassemia intermedia,” *Haematologica*, vol. 83, no. 2, pp. 118–125, 1998.

[64] L. de Franceschi, C. Brugnara, and Y. Beuzard, “Dietary magnesium supplementation ameliorates anemia in a mouse model of β-thalassemia,” *Blood*, vol. 90, no. 3, pp. 1283–1290, 1997.

[65] L. de Franceschi, F. Daraio, A. Filippini et al., “Liver expression of hepcidin and other iron genes in two mouse models of β-thalassemia,” *Haematologica*, vol. 91, no. 10, pp. 1336–1342, 2006.

[66] L. de Franceschi, F. Turrini, M. Honczarenko et al., “In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia,” *Haematologica*, vol. 89, no. 11, pp. 1287–1298, 2004.

[67] O. Shalev, T. Repka, A. Goldfarb et al., “Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo,” *Blood*, vol. 86, no. 5, pp. 2008–2013, 1995.

[68] C. B. Hyman, J. A. Ortega, G. Costin, and M. Takahashi, “The clinical significance of magnesium depletion in thalassemia,” *Annals of the New York Academy of Sciences*, vol. 344, pp. 436–443, 1980.

[69] V. Abbasciano, G. Bader, L. Graziano et al., “Serum and erythrocyte levels of magnesium in microcytosis: comparison between heterozygous beta-thalassemia and sideropenic anemia,” *Haematologica*, vol. 76, no. 4, pp. 339–341, 1991.

[70] E. A. Rachmilewitz, A. Shiffer, and I. Kahane, “Vitamin E deficiency in β-thalassemia major: changes in hematological and biochemical parameters after a therapeutic trial with α-tocopherol,” *The American Journal of Clinical Nutrition*, vol. 32, no. 9, pp. 1850–1858, 1979.

[71] I. Kahane and E. A. Rachmilewitz, “Alterations in the red blood cell membrane and the effect of vitamin E on osmotic fragility in β-thalassemia major,” *Israel Journal of Medical Sciences*, vol. 12, no. 1, pp. 11–15, 1976.

[72] L. Tesoriere, D. D’Arpa, D. Butera et al., “Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in β-thalassemia intermedia patients,” *Free Radical Research*, vol. 34, no. 5, pp. 529–540, 2001.

[73] E. Fibach and E. A. Rachmilewitz, “The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia,” *Annals of the New York Academy of Sciences*, vol. 1202, pp. 10–16, 2010.

[74] S. Srichairatanakool, C. Thephinlap, C. Phisalaphong, J. B. Porter, and S. Fucharoen, “Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma,” *Medicinal Chemistry*, vol. 3, no. 5, pp. 469–474, 2007.

[75] J. Amer, D. Atlas, and E. Fibach, “N-acetylcysteine amide (AD4) attenuates oxidative stress in beta-thalassemia blood cells,” *Biochimica et Biophysica Acta*, vol. 1780, no. 2, pp. 249–255, 2008.

[76] J. Amer, A. Goldfarb, E. A. Rachmilewitz, and E. Fibach, “Fermented papaya preparation as redox regulator in blood cells of β-thalassemic mice and patients,” *Phytotherapy Research*, vol. 22, no. 6, pp. 820–828, 2008.

[77] L. Weiss, “A rationale for an individualized administration frequency of epoetin β: a clinical perspective,” *Nephrology Dialysis Transplantation*, vol. 17, supplement 6, pp. 8–12, 2002.

[78] M. I. Lai, J. Jiang, N. Silver et al., “Alpha-haemoglobin stabilising protein is a quantitative trait gene that modifies the phenotype of beta-thalassaemia,” *The British Journal of Haematology*, vol. 133, no. 6, pp. 675–682, 2006.

[79] X. Yu, Y. Kong, L. C. Dore et al., “An erythroid chaperone that facilitates folding of alpha-globin subunits for hemoglobin synthesis,” *The Journal of Clinical Investigation*, vol. 117, no. 7, pp. 1856–1865, 2007.

[80] E. Khandros, T. L. Mollan, X. Yu et al., “Insights into hemoglobin assembly through in vivo mutagenesis of a- hemoglobin stabilizing protein,” *Journal of Biological Chemistry*, vol. 287, no. 14, pp. 11325–11337, 2012.

[81] J. I. Chen, “Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias,” *Blood*, vol. 109, no. 7, pp. 2693–2699, 2007.

[82] L. Lu, A.-P. Han, C. Yu et al., “Heme-regulated eIF2alpha kinase activated Atf4 signaling pathway in erythroid cells under cytoplasmic stresses,” *Cellular Biology*, vol. 21, no. 23, pp. 7971–7980, 2001.

[83] R. N. Suragani, R. S. Zachariah, J. G. Velazquez et al., “Heme-regulated eIF2α kinase (HR1) is required for translational regulation and survival of erythroid precursors in iron deficiency,” *EMBO Journal*, vol. 20, no. 23, pp. 6909–6918, 2001.

[84] A.-P. Han, C. Yu, L. Lu et al., “Heme-regulated eIF2α kinase (HR1) is required for translational regulation and survival of erythroid precursors in iron deficiency,” *EMBO Journal*, vol. 20, no. 23, pp. 6909–6918, 2001.

[85] R. N. Suragani, R. S. Zachariah, J. G. Velazquez et al., “Heme-regulated eIF2α kinase (HR1) is required for translational regulation and survival of erythroid precursors in iron deficiency,” *EMBO Journal*, vol. 20, no. 23, pp. 6909–6918, 2001.

[86] H. H. Jang, K. O. Lee, Y. H. Chi et al., “Two enzymes in one: two yeast peroxiredoxins display oxidative stress-dependent switching from a peroxidase to a molecular chaperone function,” *Cell*, vol. 117, no. 5, pp. 625–635, 2004.

[87] Z. A. Wood, E. Schröder, J. R. Harris, and L. B. Poole, “Structure, mechanism and regulation of peroxiredoxins,” *Trends in Biochemical Sciences*, vol. 28, no. 1, pp. 32–40, 2003.
[87] F. M. Low, M. B. Hampton, and C. C. Winterbourn, “Peroxiredoxin 2 and peroxide metabolism in the erythrocyte,” *Antioxidants and Redox Signaling*, vol. 10, no. 9, pp. 1621–1630, 2008.

[88] B. Manta, M. Hugo, C. Ortiz, G. Ferrer-Sueta, M. Trujillo, and A. Denicola, “The peroxidase and peroxynitrite reductase activity of human erythrocyte peroxiredoxin 2,” *Archives of Biochemistry and Biophysics*, vol. 484, no. 2, pp. 146–154, 2009.

[89] A. Matte, P. S. Low, F. Turrini et al., “Peroxiredoxin-2 expression is increased in β-thalassemic mouse red cells but is displaced from the membrane as a marker of oxidative stress,” *Free Radical Biology and Medicine*, vol. 49, no. 3, pp. 457–466, 2010.

[90] A. Matte, M. Bertoldi, N. Mohandas et al., “Membrane association of peroxiredoxin-2 in red cells is mediated by the N-terminal cytoplasmic domain of band 3,” *Free Radical Biology and Medicine*, vol. 55, pp. 27–35, 2013.

[91] L. de Franceschi, M. Bertoldi, L. de Falco et al., “Oxidative stress modulates heme synthesis and induces peroxiredoxin-2 as a novel cytoprotective response in β-thalassemic erythropoiesis,” *Haematologica*, vol. 96, no. 11, pp. 1595–1604, 2011.

[92] P. Zhang, B. Liu, S. W. Kang, M. S. Seo, S. G. Rhee, and L. M. Obeid, “Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2,” *Journal of Biological Chemistry*, vol. 272, no. 49, pp. 30615–30618, 1997.

[93] S. W. Kang, H. Z. Chae, M. S. Seo, K. Kim, I. C. Baines, and S. G. Rhee, “Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-α,” *Journal of Biological Chemistry*, vol. 273, no. 11, pp. 6297–6302, 1998.

[94] J. Liu, J. Zhang, Y. Ginzburg et al., “Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis,” *Blood*, vol. 121, no. 2, pp. e43–e49, 2013.

[95] S. Santos Franco, L. De Falco, S. Ghaffari et al., “Resveratrol accelerates erythroid maturation by activation of FOXO3 and ameliorates anemia in beta-thalassemic mice,” *Haematologica*, 2013.